Debunking yeti DNA, and the incredibly strong arms of prehistoric female farmers
The abominable snowman, the yeti, bigfoot, and sasquatch —these long-lived myths of giant, hairy hominids depend on dropping elusive clues to stay in the popular imagination—a blurry photo here, a big footprint there—but what happens when scientists try to pin that evidence down? Online News Editor David Grimm talks with Sarah Crespi about the lates t attempts to verify the yeti’s existence using DNA analysis of bones and hair and how this research has led to more than the debunking of a mythic creature.
Sarah also interviews Alison Macintosh of the University of Cambridge in the United Kingdom about her investiga...
Source: Science Magazine Podcast - November 30, 2017 Category: Science Authors: Science Tags: Scientific Community Source Type: podcasts
Debunking yeti DNA, and the incredibly strong arms of prehistoric female farmers
The abominable snowman, the yeti, bigfoot, and sasquatch —these long-lived myths of giant, hairy hominids depend on dropping elusive clues to stay in the popular imagination—a blurry photo here, a big footprint there—but what happens when scientists try to pin that evidence down? Online News Editor David Grimm talks with Sarah Crespi about the lates t attempts to verify the yeti’s existence using DNA analysis of bones and hair and how this research has led to more than the debunking of a mythic creature. Sarah also interviews Alison Macintosh of the University of Cambridge in the United Kingdom about her investigat...
Source: Science Magazine Podcast - November 30, 2017 Category: Science Authors: Science Tags: Scientific Community Source Type: podcasts
Treatment for hypertension in adults aged 18 to 59 years
Several drugs have been shown to lower blood pressure in people with hypertension, but it ‘s important to know the size of the benefit separately for young healthy adults aged up to 59 years and for those who are 60 or more. A Cochrane Review for the older age group has been available for some time, and Vijaya Musini from the University of British Columbia in Vancouver, Canada and coll eagues in the Cochrane Hypertension Group published the first Cochrane Review for the younger age group in August 2017. Here’s Vijaya to tell us more. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 14, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Blood pressure lowering efficacy of aliskiren
High blood pressure is a chronic condition associated with an increased risk of cardiovascular disease and death. Over the last two decades, the Cochrane Hypertension Group has produced numerous reviews of ways to treat it, including one of the effects of a class of drugs called renin inhibitors. The review was updated in April 2017 and we asked the lead author, Vijaya Musini from the University of British Columbia in Vancouver Canada, to tell us about the latest findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 14, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Treatment for hypertension in adults aged 18 to 59 years
Several drugs have been shown to lower blood pressure in people with hypertension, but it ‘s important to know the size of the benefit separately for young healthy adults aged up to 59 years and for those who are 60 or more. A Cochrane Review for the older age group has been available for some time, and Vijaya Musini from the University of British Columbia in Vancouver, Canada and coll eagues in the Cochrane Hypertension Group published the first Cochrane Review for the younger age group in August 2017. Here’s Vijaya to tell us more. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 14, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
Blood pressure lowering efficacy of aliskiren
High blood pressure is a chronic condition associated with an increased risk of cardiovascular disease and death. Over the last two decades, the Cochrane Hypertension Group has produced numerous reviews of ways to treat it, including one of the effects of a class of drugs called renin inhibitors. The review was updated in April 2017 and we asked the lead author, Vijaya Musini from the University of British Columbia in Vancouver Canada, to tell us about the latest findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - September 14, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
GKT831 - Next Steps
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the next steps for the preclinical models of GKT831
Author: Cancer-News
Added: 09/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 1, 2017 Category: Cancer & Oncology Source Type: podcasts
GKT831 Side Effects
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the relatively well tolerated GKT831 in other disease states.
Author: Cancer-News
Added: 09/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Inhibiting CAFs Not Sufficient Alone to Stop Cancer Growth
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and notes that inhibiting CAFs are not sufficient...
Author: Cancer-News
Added: 08/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2017 Category: Cancer & Oncology Source Type: podcasts
CANVAS Proves CV Safety, Metabolic Value of Canagliflozin
British diabetes expert Clifford Bailey offers his take on the CANVAS data (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - June 30, 2017 Category: Endocrinology Authors: Medscape Source Type: podcasts
SCCM Pod-343 Patient Diaries in the ICU
Dr. Ludwig Lin, MD, speaks with Christina Jones, PhD, RN, about the ICU Patient Diary Network. Dr. Jones discusses the widespread adoption of ICU diaries in the United Kingdom, various models that institutions are using, and the overall positive impact that implementation has had on patients, families, and providers. (Source: SCCM PodCast - iCritical Care)
Source: SCCM PodCast - iCritical Care - June 29, 2017 Category: Intensive Care Authors: The Society of Critical Care Medicine (SCCM) Tags: Medicine Source Type: podcasts
